We are live on ! Find out more
OXFD

Oxford Immunotec Global PLC Ordinary Shares
OXFD

Delisted

OXFD was delisted on the 5th of March, 2021.

49 hedge funds and large institutions have $178M invested in Oxford Immunotec Global PLC Ordinary Shares in 2014 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 19 increasing their positions, 17 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 17

7% less capital invested

Capital invested by funds: $192M → $178M (-$13.8M)

16% less funds holding

Funds holding: 5849 (-9)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

69% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 13

Holders
49
Holders Change
-9
Holders Change %
-15.52%
% of All Funds
1.42%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
4
Increased
19
Reduced
17
Closed
13
Calls
Puts
Net Calls
Net Calls Change

OXFD Hedge Fund Activity: Q3 2014 in Review

49 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Oxford Immunotec Global PLC Ordinary Shares (OXFD) for Q3 2014, worth a combined $178M — down 7.2% from $192M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of OXFD and 4 opened new positions — a net loss of 9 holders — while 17 trimmed existing stakes and 19 added.

The largest buyer was Tiverton Asset Management, adding an estimated $6.09M. The largest seller was Dow Chemical Company, exiting entirely with an estimated $4.64M sold.

  • 49 institutional investors held Oxford Immunotec Global PLC Ordinary Shares (OXFD) as of Q3 2014, down from 58 in Q2 2014.
  • Funds reported $178M of Oxford Immunotec Global PLC Ordinary Shares stock for Q3 2014, down 7.2% quarter-over-quarter.
  • 4 funds opened new Oxford Immunotec Global PLC Ordinary Shares positions in Q3 2014 and 13 closed out, a net change of -9 holders.
  • The largest Oxford Immunotec Global PLC Ordinary Shares buyer in Q3 2014 was Tiverton Asset Management, an estimated $6.09M added.
  • The largest Oxford Immunotec Global PLC Ordinary Shares seller in Q3 2014 was Dow Chemical Company, an estimated $4.64M sold.

Based on aggregated 13F filings for Q3 2014.